^
    Back
    Association details:
    Biomarker:ABL1 E255K
    Cancer:Acute Lymphocytic Leukemia
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Published date:
    11/06/2019
    Excerpt:
    Of the 3 relapses on ponatinib, 2 pts were found to have an E255K ABL1 kinase domain mutation and 1 pt had no mutation identified.
    DOI:
    10.1182/blood-2019-125146